ArticleJournal of neuro-oncology2026
Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeVestibular schwannoma (VS) is a non-malignant tumor arising from Schwann cells of the vestibulocochlear nerve. While not malignant, VS can significantly impact patients’ quality of life by causing hearing loss, facial paralysis, vestibular dysfunction, and impaired mobility. The resulting ataxia is particularly debilitating, often resulting in significant gait disturbances and an increased risk of falls. Current treatment options, including surgery and radiotherapy, carry risks of further damaging the surrounding cranial nerves, underscoring the need for more effective and less invasive therapeutic strategies. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their potential in non-malignant tumors like VS remains unexplored. Immune-related adverse events, particularly neurological complications such as neuroinflammation and brain edema, pose challenges for their application in VS. In this study, we aimed to evaluate the effects of anti-PD1 (αPD1) treatment on neurological symptoms.
methodsIn the cerebellopontine angle model of VS that reproduces schwannoma-induced ataxia, we used a panel of tests to evaluate the efficacy of αPD1 monotherapy and combination therapy with anti-VEGF (αVEGF) on alleviating ataxia.
resultsOur results demonstrated that αPD1 treatment alleviated ataxia in mice but also triggered a systemic immune response, leading to brain edema and inflammation. To mitigate these adverse effects and optimize αPD1 therapy, we investigated combination strategies. αVEGF treatment, known for its ability to normalize tumor vasculature, can reduce vasogenic edema of the brain and peripheral nerve and improve neurological function in VS models. Here, we demonstrated that combined αPD1 and αVEGF therapy significantly improved ataxia and inhibited the activation of the inflammatory AKT and JAK2/STAT3 signaling pathways (n=18 mice/arm in animal studies).
conclusionThese findings suggest that a combinatorial approach using αVEGF and αPD1 may reduce immunotherapy-induced neuroinflammation and neurotoxicity, offering a promising therapeutic strategy for VS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.